Skip to Content

A long-term benefit of darolutamide for patients with nmCRPC

Results from the ARAMIS rollover study have been presented at this year’s ASCO-GU23. Following a primary double-blinded analysis, these findings suggest long-term clinical benefit and tolerability for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) remaining on darolutamide for ≥4 years.

Neal Shore

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top